Anosognosia in schizophrenia: Hidden in plain sight

Innovations in Clinical Neuroscience

Volumn 11, Issue 5-6, 2014, Pages 10-17

  Lehrer, Douglas S ^a,b   Lorenz, Jennifer ^a,c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Summit Behavioral Healthcare   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Anosognosia; Cognition; Insight; Psychosis; Schizophrenia

Indexed keywords

ANOSOGNOSIA; ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; DEPRESSIVE PSYCHOSIS; HOSPITALIZATION; HUMAN; INSIGHT AND TREATMENT ATTITUDE QUESTIONNAIRE; INSULA; MENTAL DISEASE; META ANALYSIS (TOPIC); NEUROPSYCHOLOGY; PREFRONTAL CORTEX; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEMI STRUCTURED INTERVIEW; WISCONSIN CARD SORTING TEST;

EID: 84938061094     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409-1416
2. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15-and 25-year international follow-up study. Br J Psychiatry. 2001;178:506-517
3. Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2013;39(6):1363-1372
4. Buckley PF, Wirshing DA, Bhushan P, et al. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs. 2007;21(2):129-141
5. David AS. Insight and psychosis. Br J Psychiatry. 1990;156:798-808
6. Cooke MA, Peters ER, Kuipers E, Kumari V. Disease, deficit, or denial? Models of poor insight in psychosis. Acta Psychiatrica Scandinavica. 2005;112(1):4-17
7. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276
8. McEvoy JP, Freter S, Everett G, et al. Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis. 1989;177(1):48-51
9. Amador XF, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. Amer J Psychiatry. 1993;150:873-879
10. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51(10):826-836
11. Beck AT, Baruch E, Balter JM, et al. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004;68(2-3):319-329
12. Shad MU, Keshavan MS, Tamminga CA, et al. Neurobiological underpinnings of insight deficits in schizophrenia. Int Rev Psychiatry. 2007;19(4):437-446
13. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of the literature. J Clin Psychiatry. 2002;60(10):892-909
14. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071
15. Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1-3):117-121
16. Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149(9):1183-1188
17. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Cause and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry. 2000;177:511-515
18. Dell’Osso B, Glick ID, Baldwin DS, Altamura AC. Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework. Psychopathology. 2013;46(1):14-21
19. Boonstra N, Klaassen R, Sytema S, et al. Duration of untreated psychosis and negative symptoms -a systematic review and metaanalysis of individual patient data. Schizophr Res. 2012;142(1-3):12-19
20. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-351
21. Lieberman JA, Alvir KM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(3 Suppl):13S-21S.
22. Cahn W, Rais M, Stigter FP, et al. Psychosis and brain volume changes during first five years of psychosis. Eur Neuropsychopharmacol. 2009;19(2):147-151
23. Andreasen NC, Liu D, Ziebell S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609-615
24. Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res. 2004;130(1):71-78
25. Langer KG. Babinski’s anosognosia for hemiplegia in early twentiethcentury French neurology. J Hist Neurosci. 2009;18(4):387-405
26. Shad MU, Muddasani S, Keshavan MS. Prefrontal subregions and dimension of insight in firstepisode schizophrenia: a pilot study. Psychiatry Res. 2006;146(1):35-42
27. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23
28. Aleman A, Agrawal N, Morgan KD, David AS. Insight in psychosis and neuropsychological function: metaanalysis. Br J Psychiatry. 2006;189:204-212
29. Shad MU, Tamminga CA, Cullum M, et al. Insight and cortical function in schizophrenia: a review. Schizophr Res. 2006;86(1-3):54-70
30. Orfei DM, Piras F, Macci E, et al. The neuroanatomical correlates of cognitive insight in schizophrenia. Soc Cog Affect Neurosci. 2013;8(4):418-423
31. Wylie KP, Tregellas JR. The role of the insula in schizophrenia. Schizophr Res. 2010;123(2-3):93-104
32. Craig AD. How do you feel -now? The anterior insula and human awareness. Nat Rev Neurosci. 2009;10(1):59-70
33. Glahn DC, Laird AR, Ellison-Wright I, et al. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry. 2008;64(9):774-781
34. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm. 1986;65(3-4):303-326
35. Palaniyappan L, Mallikarjun P, Joseph V, Liddle PF. Appreciating symptoms and deficits in schizophrenia: right posterior insula and poor insight. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):523-527
36. Farrer C, Franck N, Frith CD, et al. Neural correlates of action attribution in schizophrenia. Psychiatry Res. 2004;131(1):31-44
37. Klein TA, Ullsperger M, Danielmeier C. Error awareness and the insula: Links to neurological and psychiatric diseases. Front Hum Neurosci. 2013;7:14
38. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain operation. Proc Natl Acad Sci USA. 2001;98(2):676-682
39. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA. 2009;106(4):1279-1284
40. Liemburg EJ, van der Meer L, Swart M, et al. Reduced connectivity in the self-processing network of schizophrenia patients with poor insight. PLoS ONE. 2012;7(8):e42707
41. Pijnenborg GH, van Donkersgoed RJ, David AS, Aleman A. Changes in insight during treatment for psychotic disorders: A metaanalysis. Schizophr Res. 2013;144(1-3):109-117
42. Gerretsen P, Diaz P, Mamo D, et al. Transient insight induction with electroconvulsive therapy in a patient with refractory schizophrenia: A case report and systematic literature review. J ECT. 2011;27(3):247-250
43. Levine J, Toder D, Geller V, et al. Beneficial effects of caloric vestibular stimulation on denial of illness and manic delusions in schizoaffective disorder: a case report. Brain Stimul. 2012;5(3):267-73
44. Kim BR, Chun MH, Kim DY, Lee SJ. Effect of high-and lowfrequency repetitive transcranial magnetic stimulation on visuospatial neglect in patients with acute stroke: a double-blind, sham-controlled trial. Arch Phys Med Rehabil. 2013;94(5):803-7.